Allergy Therapeutics Names Helge Weiner-Trapness as Executive Chairman Amid Hong Kong Dual Listing Plans

Strategic Leadership Transition at Allergy Therapeutics

Allergy Therapeutics plc has announced a major executive leadership update with Helge Weiner-Trapness assuming the role of Executive Chairman. The UK-headquartered biotechnology company, focused on allergy disorder treatment and diagnosis, revealed this change as part of its strategic growth plans. Since joining on 1 January 2026 as Chief Strategy Officer and Executive Director, Weiner-Trapness now expands his responsibilities to Chairman while continuing strategic collaboration with CEO Manuel Llobet.

Peter Jensen OBE, who has served as Non-Executive Chairman for 16 years since joining the Board in 2010 and becoming Chairman in 2011, will transition to a Non-Executive Director role to ensure a smooth handover. He will not seek re-election at the upcoming Annual General Meeting, enabling continuity of governance during this critical phase of international growth and strategic development.

Weiner-Trapness’ Extensive Investment Banking Expertise to Guide Growth

Bringing over three decades of experience in global finance and advisory, Helge Weiner-Trapness is well-positioned to lead Allergy Therapeutics’ strategic initiatives amid ambitious expansion goals. His career spans top investment banks across the US and Asia, most recently serving as Vice Chairman, Global Banking at HSBC Holdings plc, a leading global financial institution. This expertise equips him to steer the company through complex international capital markets and corporate finance challenges.

Additionally, Weiner-Trapness has contributed to the International Finance Facility for Immunisation (IFFIm), part of the Vaccine Alliance (Gavi), highlighting his engagement with global health financing. This unique blend of corporate finance and healthcare sector experience supports his leadership of Allergy Therapeutics as it pursues multi-jurisdictional growth and listings.

Dual Primary Listing Strategy on Hong Kong Stock Exchange

The appointment of Weiner-Trapness is closely linked to Allergy Therapeutics’ strategic objective to pursue a dual primary listing on The Stock Exchange of Hong Kong Limited alongside its AIM listing on the London Stock Exchange. The company states that Weiner-Trapness will provide enhanced corporate and strategic leadership as it advances this significant capital markets initiative. The potential Hong Kong listing is a pivotal move to access Asian capital markets and broaden the company’s geographic reach.

This dual listing could unlock key new markets, bolster Asian expansion, and strengthen Allergy Therapeutics’ research and development platform. The company currently operates subsidiaries and branches in nine major European countries and maintains distribution agreements in four additional countries, providing a robust foundation for its international commercial infrastructure. The selection of a chairman with deep global banking and capital markets expertise underscores the company’s commitment to navigating the regulatory and operational complexities of this strategy.

Peter Jensen OBE’s 16-Year Leadership Marked by Transformation

Peter Jensen’s retirement as Chairman concludes a transformative era for Allergy Therapeutics. Joining the Board in 2010 and chairing since 2011, Jensen oversaw significant commercial and clinical progress amid evolving regulatory frameworks for allergy immunotherapies. His tenure included guiding the company through complex regulatory changes while advancing its clinical pipeline and commercial footprint.

Jensen highlighted the company’s establishment as a market leader with a substantial portfolio and innovative pipeline, citing the recent launch of GrassmunoAE in Germany as a testament to ongoing commercial momentum. His continued presence as a Non-Executive Director during the transition reflects the Board’s desire to retain his institutional knowledge, with his decision not to stand for re-election clarifying the timeline for full leadership succession.

Robust European Commercial Presence and Product Portfolio

Operating as a fully integrated commercial biotechnology company, Allergy Therapeutics maintains a diversified presence across Europe. The Group markets proprietary and third-party allergy immunotherapy products through subsidiaries and branches in nine major European countries, supplemented by distribution agreements in four others. This extensive infrastructure supports distribution across multiple regulated markets with varying approval and reimbursement environments.

The company’s recent activities, including the launch of GrassmunoAE in Germany, demonstrate active pipeline advancement and market expansion. Allergy Therapeutics focuses on both treatment and diagnosis of allergic disorders, with a portfolio featuring aluminium-free immunotherapies aimed at potential disease cures, distinguishing its product formulations within the sector.

Adapting to a Shifting Regulatory Environment

The announcement notes a "shifting regulatory landscape for allergy immunotherapies" during Jensen’s tenure, reflecting evolving approval and reimbursement requirements across European jurisdictions. Allergy Therapeutics’ ability to navigate these diverse regulatory frameworks while progressing commercially and clinically illustrates the company’s operational strength.

Expanding into Asian markets via a Hong Kong listing introduces additional regulatory complexities, reinforcing the importance of appointing a chairman experienced in international capital markets and corporate governance. Anticipating and managing regulatory developments remain critical to the company’s future success.

CEO Manuel Llobet Maintains Operational Leadership

Manuel Llobet continues as Chief Executive Officer, overseeing day-to-day operations and commercial execution. The new dual executive structure pairs Llobet’s operational leadership with Weiner-Trapness’ strategic and board-level oversight, particularly regarding capital markets initiatives like the potential Hong Kong listing. The company states that the two will collaborate closely to drive growth and advance international strategy.

Peter Jensen expressed confidence that "with Helge's executive leadership of the Board and Manuel's continued stewardship of the Company as CEO, Allergy Therapeutics is well placed to deliver on its next phase of growth." This governance model highlights the strategic importance of the dual listing and international expansion efforts.

Inside Information Disclosure and Regulatory Compliance

The announcement is classified as containing inside information under the UK Market Abuse Regulation (EU No. 596/2014 as incorporated into UK law), indicating the Executive Chairman appointment is material non-public information potentially affecting investment decisions. CEO Manuel Llobet is designated as the responsible officer for releasing the announcement, underscoring regulatory compliance and investor protection standards for AIM-listed companies.

The timely disclosure on 28 July 2026 ensures all market participants receive the information simultaneously, preventing information asymmetry or unfair trading advantages related to this significant leadership change.

Investor Implications of Leadership and Strategic Developments

Investors should note the transition from a Non-Executive to an Executive Chairman role coincides with strategic international expansion and a potential Hong Kong dual listing. The appointment of Weiner-Trapness, with his extensive global banking and corporate finance background, suggests preparations for a major capital markets transaction or corporate restructuring. The timing indicates management’s intent to advance the dual listing initiative.

Peter Jensen’s retention as Non-Executive Director during the transition offers governance continuity, while his decision not to seek re-election sets a clear leadership succession timeline. Market participants may closely monitor developments around the Hong Kong listing, which could significantly impact capital access, shareholder composition, and market positioning. The company’s commercial momentum, evidenced by the GrassmunoAE launch and strong European market presence, provides a foundation to assess whether these strategic moves support Allergy Therapeutics’ growth objectives.